<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00171184</url>
  </required_header>
  <id_info>
    <org_study_id>CDAR328A2409</org_study_id>
    <nct_id>NCT00171184</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged &gt; 65 Years With Overactive Bladder</brief_title>
  <official_title>Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged &gt; 65 Years With Overactive Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Procter and Gamble</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the efficacy, safety and tolerability of 12-weeks
      treatment with darifenacin in patients aged &gt;Ý 65 years with OAB.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in number of urge urinary incontinence episodes (UUIE) per week at week 12.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in : number of UUIE per week at week 1, 2 and 6, number of micturitions per day at week 1,2 and 12; number of urinary incontinence pads used per week at week 1,2,6 &amp; 12; number of nocturnal voids per week at week 1,2,6 &amp; 12.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life at week 6 and/or 12.</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Darifenacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darifenacin</intervention_name>
    <description>Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Enablex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet once daily with sham titration</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptoms of OAB for at least six months prior to Visit 3

          -  Symptoms of OAB during the 7 day diary period immediately preceding Visit 3:

          -  ≥ 1 UUIE on average per day and

          -  ≥ 10 episodes of micturition on average per day

        Exclusion Criteria:

          -  A total daily urinary volume &gt; 3000 ml or a mean volume voided per micturition of &gt;
             300 ml as verified in the micturition diary before randomization

          -  Post-void residual (PVR) urinary volume &gt; 100 ml

          -  Clinically significant stress urinary incontinence as determined by the investigator

          -  Clinically significant bladder outlet obstruction as determined by the investigator

          -  Concomitant diseases in which the use of anticholinergic drugs is contraindicated,
             e.g. urinary retention, gastric retention, uncontrolled narrow-angle glaucoma,
             myasthenia gravis, severe hepatic impairment (Child Pugh B and C), severe ulcerative
             colitis, toxic megacolon.

        Other protocol inclusion / exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Chair</role>
    <affiliation>East Hanover NJ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scott Department of Urology Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2354</url>
    <description>Results for CDAR328A2409 from the Novartis Clinical Trials website</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Overactive bladder, Darifenacin, M3 muscarinic receptor antagonist, elderly population</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darifenacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

